CADTH Lecture Series: Developing a Values Based Framework for Decision Making in Technology Assessment (and Health)

Clinical and health policy decision-making requires careful consideration of a range of clinical, ethical, societal, and economic values, compounded by great uncertainty. There is a need to balance benefits and risks, weigh competing objectives, and manage within budget constraints. Join Dr. Murray Krahn, 2014 recipient of the Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment, for a discussion of the factors to be considered in developing a fair, transparent, and values-based framework for decisions about the adoption and use of health technologies.

Click here to sign up for the lecture! (Register by March 9th, 2015)

The event will take place at 1:30 p.m. EDT on March 12, 2015 in Ottawa and online via webinar. While there is no charge for attending, you do need to register before 5:00 pm on March 9, 2015. Please feel free to distribute this invitation electronically, post in your office, or share on social media.

Dr. Murray Krahn, director of THETA (Toronto Health Economics and Technology Assessment Collaborative), primary investigator of the Canadian Centre for Applied Research in Cancer Control (ARCC), the F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, Professor in the Faculties of Medicine and Pharmacy, University of Toronto, Senior Scientist the Toronto General Research Institute and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. Dr. Krahn’s research program focuses on the use of decision analytic methods to examine health policy and health decision-making. His recent research includes the development of clinical policy models, disease-specific utility instruments, and use of large administrative datasets for developing longitudinal cost models. He is also interested in methods that integrate competing scientific paradigms in the evaluation of new drugs and technologies.